Tecvayli
Tecvayli ingredients
| Active ingredient | Strength |
|---|---|
| Teclistamab | 10 mg/mL, 90 mg/mL |
What Tecvayli is used for
The FDA lists the approved uses on the official label (below). In the EU, teclistamab is approved as Tecvayli for:
Tecvayli is indicated in combination with daratumumab for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Tecvayli
- Generic name
- Teclistamab-cqyv
- Made by
- Janssen Biotech, Inc.
- Forms
- Injection
- Given
- Subcutaneous
- FDA approval
- Biologic licence (BLA) BLA761291
- On the US market since
- 2022
Official information
- Tecvayli prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Teclistamab-cqyv)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Tecvayli?
Tecvayli (Teclistamab-cqyv) is a cancer medicine made by Janssen Biotech, Inc., approved by the US FDA.
What are the ingredients of Tecvayli?
Tecvayli contains Teclistamab (10 mg/mL, 90 mg/mL).
Is Tecvayli approved in Europe?
The same active substance is approved in the EU as Tecvayli.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA